{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:22:01Z","timestamp":1784856121348,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001448","name":"Alpha-1 Foundation","doi-asserted-by":"publisher","award":["503556"],"award-info":[{"award-number":["503556"]}],"id":[{"id":"10.13039\/100001448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are limited data on economic aspects of the genetic variant of chronic obstructive pulmonary disease (COPD) in the context of the more prevalent form of COPD. The objective of this study was to isolate the healthcare resource utilization and economic burden attributable to the presence of a genetic factor among COPD patients with and without Alpha-1 Antitrypsin Deficiency (AATD), twelve months before and after their initial COPD diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of OptumLabs\u00ae Data Warehouse claims (OLDW; 2000\u20132017). The OLDW is a comprehensive, longitudinal real-world data asset with de-identified lives across claims and clinical information. AATD-associated COPD cases were matched with up to 10 unique non-AATD-associated COPD controls. Healthcare resource use and costs were assigned into the following categories: office (OV), outpatient (OP), and emergency room visits (ER), inpatients stays (IP), prescription drugs (RX), and other services (OTH). A generalized linear model was used to estimate total pre- and post-index (initial COPD diagnosis) costs from a third-party payer\u2019s perspective (2018 USD) controlling for confounders. Healthcare resource utilization was estimated using a negative binomial regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population consisted of 8881 patients (953 cases matched with 7928 controls). The AATD-associated COPD cohort had higher expenditures and use of office visits (OV) and other (OTH) services, as well as OV, outpatient (OP), emergency room (ER), and prescription drugs (RX) before and after the index date, respectively. Adjusted total all-healthcare cost ratios for AATD-associated COPD patients as compared to controls were 2.04 [95% CI: 1.60\u20132.59] and 1.98 [95% CI: 1.55\u20132.52] while the incremental cost difference totaled $6861 [95% CI: $3025 - $10,698] and $5772 [95% CI: $1940 - $9604] per patient before and after the index date, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Twelve months before and after their initial COPD diagnosis, patients with AATD incur higher healthcare utilization costs that are double the cost of similar COPD patients without AATD. This study also suggests that increased costs of AATD-associated COPD are not solely attributable to augmentation therapy use. Future studies should further explore the relationship between augmentation therapy, healthcare resource use, and other AATD-associated COPD expenditures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01523-4","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T06:03:09Z","timestamp":1600840989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-0273","authenticated-orcid":false,"given":"Jan","family":"Sieluk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Slejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Perfetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Daniel","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"1523_CR1","first-page":"e1","volume":"8","author":"A Pai","year":"2009","unstructured":"Pai A. Genomic medicine in healthcare\u2013the tip of the iceberg. Electronic Healthcare. 2009;8:e1\u2013e13.","journal-title":"Electronic Healthcare"},{"key":"1523_CR2","unstructured":"National Comprehensive Cancer Network (NCCN). Breast cancer (version 2.2016). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf#Breast_050616.indd%3ABINV-A%3A4233. Accessed 10\/20, 2016."},{"issue":"10","key":"1523_CR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/21548331.1991.11705309","volume":"26","author":"M King","year":"1991","unstructured":"King M. Localization of the early-onset breast cancer gene. Hosp Pract. 1991;26(10):121\u20136.","journal-title":"Hosp Pract"},{"key":"1523_CR4","unstructured":"American Medical Association. MYH-associated polyposis fact sheet. http:\/\/www.nchpeg.org\/documents\/crc\/11-0456%20Fact%20sheets%20(MAP).pdf. Accessed 10\/27, 2016."},{"key":"1523_CR5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.8465203","volume":"260","author":"S Shirasawa","year":"1993","unstructured":"Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated ki-ras. science. 1993;260:85.","journal-title":"science"},{"key":"1523_CR6","unstructured":"World Health Organization. Chronic obstructive pulmonary disease (COPD). http:\/\/www.who.int\/respiratory\/copd\/en\/. Accessed 10\/19, 2016."},{"issue":"5","key":"1523_CR7","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1164\/ajrccm.160.5.9901055","volume":"160","author":"A Dirksen","year":"1999","unstructured":"Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of \u03b11-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5):1468\u201372.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1523_CR8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1155\/2012\/920918","volume":"19","author":"D Marciniuk","year":"2012","unstructured":"Marciniuk D, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian thoracic society clinical practice guideline. Can Respir J. 2012;19(2):109\u201316.","journal-title":"Can Respir J"},{"key":"1523_CR9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/COPD.S8577","volume":"4","author":"AR Tonelli","year":"2009","unstructured":"Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the alpha-1 foundation DNA and tissue bank. Int J Chron Obstruct Pulmon Dis. 2009;4:443\u201352.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"1523_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/15412550902905961","volume":"6","author":"KR Chapman","year":"2009","unstructured":"Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for \u03b11 antitrypsin deficiency: a meta-analysis. COPD: J Chron Obstruct Pulmon Dis. 2009;6(3):177\u201384.","journal-title":"COPD: J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"1523_CR11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1378\/chest.118.5.1480","volume":"118","author":"J Lieberman","year":"2000","unstructured":"Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest J. 2000;118(5):1480\u20135.","journal-title":"Chest J"},{"issue":"2","key":"1523_CR12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000196395","volume":"62","author":"P Stone","year":"1995","unstructured":"Stone P, Morris T III, Franzblau C, Snider G. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans. Respiration. 1995;62(2):76\u20139.","journal-title":"Respiration"},{"issue":"11","key":"1523_CR13","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1164\/rccm.2109013","volume":"165","author":"RA Stockley","year":"2002","unstructured":"Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in \u03b1 1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165(11):1494\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1523_CR14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1465-9921-11-136","volume":"11","author":"RA Stockley","year":"2010","unstructured":"Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010;11(1):136.","journal-title":"Respir Res"},{"key":"1523_CR15","unstructured":"World Health Organization. Chronic respiratory diseases. burden of COPD. http:\/\/www.who.int\/respiratory\/copd\/burden\/en\/. Accessed 8\/29, 2018."},{"issue":"5","key":"1523_CR16","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","volume":"157","author":"TA Seemungal","year":"1998","unstructured":"Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418\u201322.","journal-title":"Am J Respir Crit Care Med"},{"key":"1523_CR17","unstructured":"Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance---united states, 1971--2000. Respir Care. 2002;47(10):1184\u201399."},{"issue":"1","key":"1523_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1378\/chest.14-1976","volume":"147","author":"DM Mannino","year":"2015","unstructured":"Mannino DM. Counting costs in COPD: what do the numbers mean? Chest J. 2015;147(1):3\u20135.","journal-title":"Chest J"},{"issue":"5","key":"1523_CR19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1378\/chest.118.5.1278","volume":"118","author":"DE Hilleman","year":"2000","unstructured":"Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest J. 2000;118(5):1278\u201385.","journal-title":"Chest J"},{"issue":"1","key":"1523_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1378\/chest.14-0972","volume":"147","author":"ES Ford","year":"2015","unstructured":"Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged\u2265 18 years in the United States for 2010 and projections through 2020. Chest J. 2015;147(1):31\u201345.","journal-title":"Chest J"},{"issue":"3","key":"1523_CR21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1164\/rccm.201108-1428CI","volume":"185","author":"JK Stoller","year":"2012","unstructured":"Stoller JK, Aboussouan LS. A review of \u03b11-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185(3):246\u201359.","journal-title":"Am J Respir Crit Care Med"},{"issue":"sup1","key":"1523_CR22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/15412555.2013.771956","volume":"10","author":"C Laurell","year":"2013","unstructured":"Laurell C, Eriksson S. The electrophoretic \u03b11-globulin pattern of serum in \u03b11-antitrypsin deficiency. COPD. 2013;10(sup1):3\u20138.","journal-title":"COPD"},{"issue":"9478","key":"1523_CR23","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/S0140-6736(05)66781-5","volume":"365","author":"JK Stoller","year":"2005","unstructured":"Stoller JK, Aboussouan LS. \u03911-antitrypsin deficiency. Lancet. 2005;365(9478):2225\u201336.","journal-title":"Lancet"},{"issue":"3","key":"1523_CR24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1378\/chest.89.3.370","volume":"89","author":"J Lieberman","year":"1986","unstructured":"Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin pi-types in 965 COPD patients. Chest. 1986;89(3):370\u20133.","journal-title":"Chest."},{"issue":"1","key":"1523_CR25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-3-16","volume":"3","author":"L Fregonese","year":"2008","unstructured":"Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008;3(1):16.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1523_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1542\/peds.62.1.22","volume":"62","author":"T Sveger","year":"1978","unstructured":"Sveger T. Alpha 1-antitrypsin deficiency in early childhood. Pediatrics. 1978;62(1):22\u20135.","journal-title":"Pediatrics."},{"issue":"3","key":"1523_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.15326\/jcopdf.3.3.2015.0182","volume":"3","author":"RA Sandhaus","year":"2016","unstructured":"Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668\u201382. https:\/\/doi.org\/10.15326\/jcopdf.3.3.2015.0182.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"1523_CR28","unstructured":"Sieluk J, Levy J, Sandhaus RA, Silverman H, Holm K, Mullins CD. Medical costs of alpha-1 antitrypsin deficiency: evidence from a large commercially insured cohort in the U.S. [in press]. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2019."},{"key":"1523_CR29","doi-asserted-by":"crossref","unstructured":"Hilgers R, K\u00f6nig F, Molenberghs G, Senn S. Design and analysis of clinical trials for small rare disease populations. J Rare Dis Res Treat. 2016;1(3):53\u201360.","DOI":"10.29245\/2572-9411\/2016\/3.1054"},{"issue":"9","key":"1523_CR30","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142\u201350.","journal-title":"J Child Neurol"},{"issue":"25","key":"1523_CR31","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/sim.5428","volume":"31","author":"JS Witte","year":"2012","unstructured":"Witte JS. Rare genetic variants and treatment response: sample size and analysis issues. Stat Med. 2012;31(25):3041\u201350.","journal-title":"Stat Med"},{"issue":"4","key":"1523_CR32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jclinepi.2007.07.008","volume":"61","author":"J Van der Lee","year":"2008","unstructured":"Van der Lee J, Wesseling J, Tanck M, Offringa M. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. J Clin Epidemiol. 2008;61(4):324\u201330.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1523_CR33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","volume":"96","author":"RC Griggs","year":"2009","unstructured":"Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20\u20136.","journal-title":"Mol Genet Metab"},{"key":"1523_CR34","unstructured":"OptumLabs. OptumLabs and OptumLabs data warehouse (OLDW) descriptions and citation. cambridge, MA: N.p., june 2017. PDF. reproduced with permission from OptumLabs. ."},{"issue":"12","key":"1523_CR35","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"1523_CR36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","volume":"61","author":"ME Charlson","year":"2008","unstructured":"Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234\u201340.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"1523_CR37","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351.","journal-title":"J Clin Epidemiol"},{"key":"1523_CR38","volume-title":"Health econometrics using stata","author":"P Deb","year":"2017","unstructured":"Deb P, Norton EC, Manning WG. Health econometrics using stata. TX: Stata Press College Station; 2017."},{"issue":"1","key":"1523_CR39","first-page":"1","volume":"3","author":"S Sapra","year":"2005","unstructured":"Sapra S. A regression error specification test (RESET) for generalized linear models. Econ Bull. 2005;3(1):1\u20136.","journal-title":"Econ Bull"},{"issue":"3","key":"1523_CR40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1378\/chest.15-0721","volume":"148","author":"A Khakban","year":"2015","unstructured":"Khakban A, Sin DD, FitzGerald JM, et al. Ten-year trends in direct costs of COPD: a population-based study. Chest J. 2015;148(3):640\u20136.","journal-title":"Chest J"},{"key":"1523_CR41","doi-asserted-by":"crossref","unstructured":"European Organisation for Rare Diseases (EURORDIS). Rare diseases: Understanding this public health priority. http:\/\/www.eurordis.org\/IMG\/pdf\/princeps_document-EN.pdf. Accessed 8\/22, 2017.","DOI":"10.21820\/23987073.2017.4.12"},{"issue":"3","key":"1523_CR42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1378\/chest.119.3.745","volume":"119","author":"CD Mullins","year":"2001","unstructured":"Mullins CD, Huang X, Merchant S, Stoller JK. The direct medical costs of \u03b11-antitrypsin deficiency. Chest. 2001;119(3):745\u201352.","journal-title":"Chest"},{"issue":"1","key":"1523_CR43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12931-017-0543-8","volume":"18","author":"FM Karl","year":"2017","unstructured":"Karl FM, Holle R, Bals R, et al. Costs and health-related quality of life in alpha-1-antitrypsin deficient COPD patients. Respir Res. 2017;18(1):60.","journal-title":"Respir Res"},{"issue":"2","key":"1523_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5455\/msm.2012.24.112-120","volume":"24","author":"G Ridic","year":"2012","unstructured":"Ridic G, Gleason S, Ridic O. Comparisons of health care systems in the united states, germany and canada. Mater Sociomed. 2012;24(2):112\u201320. https:\/\/doi.org\/10.5455\/msm.2012.24.112-120.","journal-title":"Mater Sociomed"},{"issue":"3","key":"1523_CR45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1377\/hlthaff.10.3.22","volume":"10","author":"GJ Schieber","year":"1991","unstructured":"Schieber GJ, Poullier JP, Greenwald LM. Health care systems in twenty-four countries. Health Aff. 1991;10(3):22\u201338.","journal-title":"Health Aff"},{"key":"1523_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/CEOR.S34321","volume":"5","author":"AJ Guarascio","year":"2013","unstructured":"Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235\u201345. https:\/\/doi.org\/10.2147\/CEOR.S34321.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9434","key":"1523_CR47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(04)16855-4","volume":"364","author":"RA Pauwels","year":"2004","unstructured":"Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364(9434):613\u201320.","journal-title":"Lancet"},{"issue":"1","key":"1523_CR48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/15412550802607410","volume":"6","author":"MA Campos","year":"2009","unstructured":"Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD: J Chron Obstruct Pulmon Dis. 2009;6(1):31\u201340.","journal-title":"COPD: J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"1523_CR49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/intqhc\/mzl052","volume":"18","author":"L Steuten","year":"2006","unstructured":"Steuten L, Vrijhoef B, Merode FV, Wesseling G, Spreeuwenberg C. Evaluation of a regional disease management programme for patients with asthma or chronic obstructive pulmonary disease. Int J Qual Health Care. 2006;18(6):429\u201336.","journal-title":"Int J Qual Health Care"},{"issue":"7","key":"1523_CR50","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1164\/rccm.200910-1579OC","volume":"182","author":"KL Rice","year":"2010","unstructured":"Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010;182(7):890\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1523_CR51","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1378\/chest.128.4.1989","volume":"128","author":"JK Stoller","year":"2005","unstructured":"Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of \u03b11-antitrypsin deficiency: a continuing problem. Chest J. 2005;128(4):1989\u201394.","journal-title":"Chest J"},{"issue":"3","key":"1523_CR52","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1378\/chest.128.3.1179","volume":"128","author":"MA Campos","year":"2005","unstructured":"Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with \u03b11-antitrypsin deficiency between 1968 and 2003. Chest J. 2005;128(3):1179\u201386.","journal-title":"Chest J"},{"issue":"4","key":"1523_CR53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1753465811404919","volume":"5","author":"J Molina","year":"2011","unstructured":"Molina J, Flor X, Garc\u00eda R, Timiraos R, Tirado-Conde G, Miravitlles M. The IDDEA project: a strategy for the detection of alpha-1 antitrypsin deficiency in COPD patients in the primary care setting. Ther Adv Respir Dis. 2011;5(4):237\u201343.","journal-title":"Ther Adv Respir Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01523-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01523-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01523-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T20:34:58Z","timestamp":1668890098000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01523-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01523-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.19162\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19162\/v2","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"13 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional Review Board (IRB) approval was obtained from the IRB of the University of Maryland, Baltimore, on July 27, 2016 (HP-00068329).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jan Sieluk: Research funding from Bayer HealthCare (recipient: University of Maryland, Baltimore), research funding from AlphaNet (recipient: University of Maryland, Baltimore), research funding from Alpha-1 Foundation (recipient: University of Maryland, Baltimore), research funding from American Association of Colleges of Pharmacy (recipient: University of Maryland, Baltimore);Julia F. Slejko: JFS has received funding for research unrelated to the study from Novartis Pharmaceuticals Corporation, Takeda pharmaceuticals, PhRMA and PhRMA Foundation as well as teaching honorarium from Pfizer, Inc., unrelated to study.Eleanor Perfetto: Dr. Perfetto is employed by the National Health Council which receives membership duesand sponsorship support from a variety of organizations. To see the membership and sponsorship organizations, please see\n                      \n                      . Dr. Perfetto has also received grant and contract support from the FDA, Excerpta Medica, and Pfizer Inc.C. Daniel Mullins: Research funding from AlphaNet, Alpha-1 Foundation, Amgen, Bayer, Merck, Novartis, Pfizer (recipient: University of Maryland, Baltimore), consulting income from Amgen, Bayer, Janssen\/Johnson & Johnson, MundiPharma, Novartis, Pfizer, Regeneron\/Sanofi-Aventis. Robert A. Sandhaus: Medical Director of AlphaNet; medical advisor to Grifols, CSL Behring, Shire, Octapharma, Inhibrx, AstraZeneca; grants from NIH, CSL Behring, Grifols, Matrx.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}